Investor Presentaiton
R&D focus: Strong pipeline & Platform with over 2300 Scientist & Quality team
US/EU pipeline by Addressable market
R&D spent & Filing trend
$ 49 bn
60
61
73
79
82
DMFs
26
27
31
37
38
ANDAS
$ 28bn
60%
Non-ARV
5.7%
3.8%
4.1%
3.5%
4.4%
-75%
Non-ARV
25% ARV
Approved (55)^
202
211
184
160
1
105
40% ARV
FY20
FY21 FY22
■R&D spends (Cr)
Pending/Underdevelopment
(62)
6500+ Total talent pool
With over 1/3rd of total workforce into
R&D, Quality and Regulatory
1H1 FY24 results includes CGT related spends of 6 Cr
10
Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023
FY23
1HFY24
As % to Sales
1050
R&D
Scientists
218
Patents
Granted
US Filings by Therapy Mix
16%
8%
8%
Total Filed
38
53%
16%
Para IV: 16
FTFs: 11
* Total filings: EU
(18) & Canada (21)
■ARV Anti-Diab. CVS CNS Others
75+
Launches
DS and DP
LAURUS Labs
Knowledge. Innovation. ExcellenceView entire presentation